We can’t show the full text here under this license.
Abstract
GEMap integrates 1912 CRISPR screens across 1135 cancer cell lines with extensive drug and genomic data to identify therapeutic targets.
- GEMap combines genome-wide essentiality profiles with multi-omics data to enhance drug discovery.
- The platform allows exploration of different types of gene data across various cancer cell lines and tissues.
- It quantifies genetic dependencies to prioritize therapeutic targets in specific cancer types, such as those with mutations.
- GEMap facilitates the identification of tailored treatments by leveraging large-scale drug data and targets.
- It represents a novel open-access resource for advancing precision oncology against challenging targets.
Simplified